دورية أكاديمية
أعرض في EDS

High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.

التفاصيل البيبلوغرافية
العنوان: High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
المؤلفون: Donato ML; Department of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. mdonato@mdanderson.org, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC Jr, Gajewski JL, Champlin RE
المصدر: Gynecologic oncology [Gynecol Oncol] 2001 Sep; Vol. 82 (3), pp. 420-6.
نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print Cited Medium: Print ISSN: 0090-8258 (Print) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, Academic Press.
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Ovarian Neoplasms/*drug therapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dose-Response Relationship, Drug ; Female ; Hematopoietic Stem Cell Mobilization ; Humans ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/therapy ; Ovarian Neoplasms/therapy ; Survival Rate ; Topotecan/administration & dosage ; Topotecan/adverse effects
مستخلص: Objective: The goal of this study was to determine the optimal dose of topotecan when used in combination with high-dose melphalan and cyclophosphamide (TMC), and to assess the toxicity and efficacy of the regimen in patients with advanced ovarian cancer.
Methods: Fifty-three patients with persistent or recurrent ovarian cancer were treated. Disease status at study entry included: platinum-sensitive recurrent disease (15 patients), platinum-resistant or refractory recurrent disease (15 patients), positive second-look surgery (16 patients), failure to achieve a primary clinical complete response (CR) (7 patients). Following stem cell mobilization and collection, patients were given cyclophosphamide 1 g/m(2)/day on Days -6, -5, -4; melphalan 70 mg/m(2)/day on Days -3, -2; and topotecan at escalating doses from 1.25 to 4.0 mg/m(2)/day on Days -6 to -2. Peripheral blood stem cells were infused on Day 0.
Results: The optimal topotecan dose selected for future trials was 4.0 mg/m(2)/day x 5 days. The regimen had acceptable toxicity with no regimen-related death. Toxicity (Bearman toxicity criteria) was limited mostly to grade 1-2 mucositis and diarrhea. The overall response rate of patients with measurable or evaluable disease was 93%. Median survival has not yet been reached, but with a median follow up of 18 months (range: 11-37) 77% of patients are alive.
Conclusion: With a topotecan dose of 4.0 mg/m(2)/day x 5 days, the TMC regimen has acceptable toxicity and produces high response rates. In the setting of ovarian cancer, high-dose chemotherapy should be administered only as part of well-designed clinical trials. TMC should be considered a potential regimen for future randomized trials in patients with advanced ovarian cancer.
(Copyright 2001 Academic Press.)
المشرفين على المادة: 7M7YKX2N15 (Topotecan)
8N3DW7272P (Cyclophosphamide)
Q41OR9510P (Melphalan)
SCR Protocol: TMC regimen
تواريخ الأحداث: Date Created: 20010825 Date Completed: 20010920 Latest Revision: 20131121
رمز التحديث: 20240628
DOI: 10.1006/gyno.2001.6326
PMID: 11520135
قاعدة البيانات: MEDLINE
الوصف
تدمد:0090-8258
DOI:10.1006/gyno.2001.6326